Kiora Pharmaceuticals Inc.

Company Overview

Business Model: Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapies for retinal diseases. The company's primary revenue generation mechanisms currently stem from collaboration agreements and government grants, with future potential for product sales upon successful clinical development and regulatory approval of its product candidates.

Market Position: Kiora Pharmaceuticals, Inc. is developing KIO-301, a potential vision-restoring small molecule photoswitch, with an initial focus on later stages of vision loss due to retinitis pigmentosa (RP). KIO-301 has received Orphan Drug Designation from the United States Food and Drug Administration (FDA) and Orphan Medicinal Product Designation from the European Medicines Agency (EMA) for non-syndromic and syndromic rod-dominant retinal dystrophies, including RP. The company is also developing KIO-104, a novel, potent, non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) for retinal inflammatory diseases such as Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis. KIO-101, an ophthalmic topical eye drop for Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+), is currently seeking a strategic partner.

Recent Strategic Developments:

• KIO-301 Partnership: In January 2024, Kiora Pharmaceuticals, Inc. entered into a strategic co-development and commercialization agreement with Théa Open Innovation (TOI), a sister company of Laboratories Théa. This agreement grants TOI global rights (excluding certain countries in Asia) to co-develop and commercialize KIO-301 in ophthalmology. Kiora Pharmaceuticals, Inc. received an upfront payment of $16 million and is eligible for up to $285 million in clinical development, regulatory, and commercial milestone payments, plus tiered commercial royalties up to the low 20% on net sales. TOI is responsible for all KIO-301 research and development costs.
• KIO-301 Clinical Advancement: In October 2024, in collaboration with TOI, Kiora Pharmaceuticals, Inc. received regulatory approval to initiate a Phase 2 clinical trial (ABACUS-2) for KIO-301 in patients with retinitis pigmentosa. This 36-patient, multi-center, double-masked, randomized, controlled, multiple-dose study is expected to begin enrollment in the first half of 2025.
• KIO-301 Orphan Designations: KIO-301 was granted Orphan Drug Designation by the FDA in March 2022. In July 2024, it received Orphan Medicinal Product Designation by the EMA for non-syndromic, rod-dominant retinal dystrophies, which was expanded in September 2024 to include syndromic, rod-dominant retinal dystrophies.
• KIO-104 Clinical Advancement: Kiora Pharmaceuticals, Inc. is approved to initiate enrollment in a Phase 2 trial for KIO-104 in retinal inflammation, with enrollment expected to commence in the first half of 2025.
• Asset Prioritization: In July 2024, Kiora Pharmaceuticals, Inc. ceased continued development of KIO-201 and is actively pursuing partnership opportunities for its KIO-101 program.

Geographic Footprint: Kiora Pharmaceuticals, Inc. operates as a single geographic segment. Its principal executive office is located in Encinitas, California, United States. The company also maintains offices in Adelaide, Australia, and Vienna, Austria. In March 2025, Kiora Pharmaceuticals, Inc. entered into a new lease in Encinitas, California, and in January 2025, it entered into new leases in Perth, Australia, and Brisbane, Australia. The partnership with TOI for KIO-301 covers global development and commercialization rights, excluding certain countries in Asia. Kiora Pharmaceuticals, Inc. is eligible for refundable tax incentives associated with research and development expenses in Austria and Australia.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not explicitly disclosed.
• Operating Margin: 28.15% (2024)
• Net Margin: 22.44% (2024)

Investment in Growth:

• R&D Expenditure: $7,842,207 (48.95% of revenue)
• Capital Expenditures: $6,256
• Strategic Investments: Kiora Pharmaceuticals, Inc. received an upfront payment of $16 million from Théa Open Innovation in January 2024 as part of the KIO-301 co-development and commercialization agreement.

Business Segment Analysis

Kiora Pharmaceuticals, Inc. operates and manages its business as a single operating segment, focused on the development of innovative ophthalmic pharmaceutical products. Within this segment, the company is advancing several key product candidates:

KIO-301

Financial Performance:

• Revenue: $16.0 million (from upfront payment of the Théa Open Innovation partnership in 2024).
• Key Growth Drivers: Positive Phase 1b clinical trial results demonstrating safety, tolerability, and improvements in vision (visual fields, acuity, light perception, functional vision tests, neural activity, quality of life). Orphan Drug Designation from the FDA and Orphan Medicinal Product Designation from the EMA. Strategic partnership with Théa Open Innovation, which covers all future research and development costs for KIO-301. Regulatory approval to initiate a Phase 2 clinical trial (ABACUS-2) in H1 2025.

Product Portfolio:

• KIO-301 is a novel small molecule "photoswitch" designed to restore vision in patients with inherited and age-related degenerative retinal diseases. It selectively enters viable downstream retinal ganglion cells and converts them into light-sensing cells.
• Initial focus: Retinitis pigmentosa (RP), including non-syndromic and syndromic rod-dominant retinal dystrophies.
• Potential market expansion: Geographic atrophy (GA), an advanced stage of age-related dry macular degeneration.

Market Dynamics:

• Retinitis Pigmentosa: Affects approximately 1 in 3,500 people worldwide, estimated at 2.3 million globally and 97,571 in the U.S. No approved therapies currently exist.
• Geographic Atrophy: Affects approximately 1 million patients in the U.S. with no approved therapies.
• KIO-301 aims to address these unmet needs by conferring light sensitivity to downstream retinal cells where photoreceptors have degenerated.

KIO-104

Financial Performance:

• Revenue: No direct revenue reported for 2024 or 2023.
• Key Growth Drivers: Data from a Phase 1b/2a study (reported October 2022) showed a single intravitreal injection decreased intraocular inflammation, improved visual acuity, and reduced macular edema, with an excellent safety profile. Approved to initiate a Phase 2 clinical trial in H1 2025.

Product Portfolio:

• KIO-104 is a third-generation, novel, and potent non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH), formulated for intravitreal delivery.
• Designed to suppress overactive T-cell activity to treat underlying inflammation.

Market Dynamics:

• Diabetic Macular Edema (DME): Affects approximately 750,000 Americans.
• Posterior Non-Infectious Uveitis: Approximately 0.2 million cases annually in the U.S., UK, and EU.
• Current treatments for DME involve chronic steroid use or anti-VEGF treatments. KIO-104 aims to offer a best-in-class immune-modulating mechanism to overcome side effects of existing DHODH inhibitors.

KIO-101

Financial Performance:

• Revenue: No direct revenue reported for 2024 or 2023.
• Key Growth Drivers: Top-line safety and tolerability data from a Phase 1b proof-of-concept study in patients with ocular surface inflammation (reported Q4 2021) showed zero clinically significant laboratory findings. Kiora Pharmaceuticals, Inc. is actively seeking a strategic partner for its continued development.

Product Portfolio:

• KIO-101 is a topical ophthalmic eye drop formulation containing the same active pharmaceutical ingredient as KIO-104.
• Focuses on treating the ocular manifestation of autoimmune diseases, termed Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).

Market Dynamics:

• Rheumatoid Arthritis (RA) patients experience ocular signs and symptoms at 2-3 times the rate of the general population, with over 0.5 million in the U.S. seeking prescription medication for ophthalmic manifestations. KIO-101 aims to target T-cell mediated auto-inflammatory diseases.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Kiora Pharmaceuticals, Inc. did not purchase any of its registered equity securities during the fiscal years ended December 31, 2024, or 2023.
• Dividend Payments: Kiora Pharmaceuticals, Inc. has never declared or paid cash dividends on its capital stock and currently intends to retain all future earnings to finance business growth and development.
• Future Capital Return Commitments: No specific future capital return commitments were disclosed.

Balance Sheet Position:

• Cash and Equivalents: $3,792,322 (as of December 31, 2024)
• Total Short-Term Investments: $22,999,760 (as of December 31, 2024)
• Total Liabilities: $10,724,708 (as of December 31, 2024). No long-term debt is explicitly disclosed in the balance sheet.
• Net Cash Position: Not explicitly stated, but total cash and short-term investments were $26,792,082 as of December 31, 2024.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: In March 2025, Kiora Pharmaceuticals, Inc. entered into a $10.0 million revolving credit line with UBS, bearing interest at the 30-day Secured Overnight Financing Rate (SOFR) average plus 1.5%. This credit line is secured by the company’s marketable securities held with UBS.

Cash Flow Generation:

• Operating Cash Flow: $8,559,115 (Net Cash Provided by Operating Activities for 2024)
• Free Cash Flow: Not explicitly disclosed.
• Cash Conversion Metrics: Not explicitly disclosed.

Operational Excellence

Production & Service Model: Kiora Pharmaceuticals, Inc. does not possess in-house manufacturing capabilities. The company relies heavily on third-party contract manufacturers for sourcing raw materials, producing, and packaging its product candidates. This model extends to the manufacturing of various components for KIO-104, KIO-301, and other contemplated clinical trials.

Supply Chain Architecture:

• Key Suppliers & Partners: Kiora Pharmaceuticals, Inc. depends on third-party contract manufacturers and suppliers for its product candidates. Specific company names for manufacturing partners were not disclosed beyond the general reliance on third parties.
• Technology Partners:
  • Photoswitch Therapeutics, Inc.: Grants Kiora Pharmaceuticals, Inc. access to patent applications and intellectual property rights related to KIO-301.
  • University of California: Grants Kiora Pharmaceuticals, Inc. exclusive rights to its pipeline of photoswitch molecules, including those for KIO-301.
  • Théa Open Innovation: Strategic co-development and commercialization partner for KIO-301.
  • Choroideremia Research Foundation (CRF): Collaborates to support strategic development of KIO-301 in Choroideremia, assisting with access to clinical and scientific thought leaders and patient enrollment for future trials.
  • 4SC: Out-license agreement for the compound used in KIO-101 and KIO-104 for rheumatoid arthritis and inflammatory bowel disease. Also, a patent and know-how assignment agreement transferring rights to the compound used in KIO-101 and KIO-104 to Kiora Pharmaceuticals, Inc.

Facility Network:

• Manufacturing: Kiora Pharmaceuticals, Inc. utilizes third-party manufacturing facilities for its products.
• Research & Development: The company conducts its operations using third-party trial sites. It maintains offices in Encinitas, California (principal executive office), Adelaide, Australia, and Vienna, Austria. New leases were entered into in January 2025 for offices in Perth, Australia, and Brisbane, Australia, and in March 2025 for a new office in Encinitas, California.
• Distribution: If KIO-104 or KIO-301 (in non-partnered territories) are approved for commercial sale, Kiora Pharmaceuticals, Inc. may enter into additional agreements with third parties for distribution or establish its own sales and marketing force.

Operational Metrics: No specific operational metrics such as capacity utilization or efficiency measures were disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy:

• Direct Sales: If KIO-104 or KIO-301 (in territories not covered by the Théa Open Innovation partnership) are approved, Kiora Pharmaceuticals, Inc. may choose to market these directly to physicians in the U.S. or globally through its own sales and marketing force. This would require significant additional expenses and management resources.
• Channel Partners:
  • Théa Open Innovation (TOI): Kiora Pharmaceuticals, Inc. has granted TOI exclusive worldwide development and commercialization rights for KIO-301 (excluding certain countries in Asia). This partnership is a key channel for KIO-301's market access.
  • 4SC: Kiora Pharmaceuticals, Inc. has an out-license agreement with 4SC for the exclusive worldwide right to commercialize the compound used in KIO-101 and KIO-104 for rheumatoid arthritis and inflammatory bowel disease.
• Digital Platforms: Not explicitly mentioned in the filing.

Customer Portfolio:

• Enterprise Customers: Not explicitly named in the filing.
• Strategic Partnerships: Key strategic partnerships include Théa Open Innovation for KIO-301, and the Choroideremia Research Foundation to support KIO-301 development in Choroideremia.
• Customer Concentration: Not explicitly disclosed.

Geographic Revenue Distribution:

• Kiora Pharmaceuticals, Inc. has recognized collaboration revenue from U.S. and foreign government grants, as well as from license and research collaboration agreements. The partnership with Théa Open Innovation for KIO-301 covers global rights, excluding certain countries in Asia. The company is eligible for R&D tax incentives in Austria and Australia.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. The development and commercialization of new drug products are highly competitive.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: Kiora Pharmaceuticals, Inc. faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions and governmental agencies. Many competitors possess significantly greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing.

• Company Name: Large pharmaceutical and biotechnology companies developing products for similar disease indications.
• Company Name: Specialty pharmaceutical and generic drug companies.
• Company Name: Academic institutions and research organizations.

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions could emerge. Competitors may develop products that are safer, more effective, have fewer side effects, are more convenient, or are less expensive. They may also obtain regulatory approval more rapidly.

Competitive Response Strategy: Kiora Pharmaceuticals, Inc. believes its technologies, knowledge, experience, and scientific resources provide competitive advantages. The company's strategy involves developing core assets, increasing equity value through collaborations, and pursuing strategic partnerships for new indications and intellectual property.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Product Acceptance: Even if approved, KIO-104, KIO-301, or other product candidates may fail to achieve sufficient market acceptance by physicians, patients, and third-party payors.
• Market Opportunity: The actual market for product candidates may be smaller than estimated, limiting potential revenue and profitability.
• Competition: Substantial competition from companies with greater resources and expertise could lead to competitors developing and commercializing superior products or obtaining approvals faster.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Heavy reliance on third-party contract manufacturers for raw materials, production, and packaging. Limited number of potential replacement manufacturers could lead to increased costs and delays if existing manufacturers become unavailable.
• Manufacturing Compliance: Third-party manufacturers may fail to comply with current Good Manufacturing Practice (CGMP) regulations, leading to sanctions, delays, or product recalls.
• Capacity Constraints: Not explicitly mentioned, but inherent in reliance on third-party manufacturing.

Financial & Regulatory Risks

Market & Financial Risks:

• Operating Losses: Kiora Pharmaceuticals, Inc. has incurred significant operating losses since inception and expects to continue incurring losses for the foreseeable future.
• Funding Requirements: Substantial additional funding will be needed for continued clinical development and potential commercialization. Inability to raise capital on favorable terms could force delays, reductions, or elimination of development programs.
• Foreign Exchange: Subject to risks of fluctuating foreign currency exchange rates (U.S. dollar, euro, Australian dollar) which could negatively impact financial results.
• Credit & Liquidity: As of December 31, 2024, Kiora Pharmaceuticals, Inc. had $26.8 million in cash and short-term investments, which management believes will fund operations into 2027. However, acceleration or reduction of cash outflows could impact this timing. Regulatory & Compliance Risks:
• Approval Process: The FDA and foreign regulatory approval processes are expensive, time-consuming, and uncertain. Failure to obtain or delays in obtaining approvals would materially impair revenue generation.
• Post-Approval Restrictions: Approved products are subject to ongoing review and extensive regulation, including restrictions on manufacturing, marketing, and promotion, which could limit sales.
• Product Liability: Inherent risk of product liability exposure from clinical trials and commercial sales, potentially leading to substantial liabilities and limiting commercialization.
• Healthcare Laws: Relationships with customers and payors are subject to anti-kickback, fraud and abuse, false claims, transparency, and privacy laws, which could result in significant penalties.
• Healthcare Reform: Current and future legislation aimed at cost containment and pricing pressures could adversely affect the ability to commercialize products profitably.

Geopolitical & External Risks

Geopolitical Exposure:

• Geographic Dependencies: Operations in Australia and Austria subject to local laws and regulations.
• Trade Relations: Not explicitly mentioned.
• Sanctions & Export Controls: Laws and regulations governing international operations, such as the Foreign Corrupt Practices Act (FCPA), may restrict development, manufacturing, and sales outside the U.S. and require costly compliance programs.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Photoswitch Molecules: KIO-301, a small molecule photoswitch, is designed to restore vision in patients with inherited and age-related degenerative retinal diseases by conferring light sensitivity to retinal ganglion cells.
• DHODH Inhibitors: KIO-104 and KIO-101 are next-generation, non-steroidal, immunomodulatory small-molecule inhibitors of dihydroorotate dehydrogenase (DHODH), targeting retinal inflammatory diseases and ocular manifestations of autoimmune diseases, respectively.
• Innovation Pipeline: KIO-301 is advancing to a Phase 2 clinical trial for retinitis pigmentosa. KIO-104 is approved to initiate a Phase 2 clinical trial for retinal inflammation. KIO-101 is seeking a partnership for further development.

Intellectual Property Portfolio:

• Patent Strategy: Kiora Pharmaceuticals, Inc. actively seeks and maintains patent protection in the U.S. and internationally for its product candidates, methods of use, and manufacturing processes. The company also relies on trade secrets, know-how, and in-licensing opportunities.
• Patent Holdings: The company holds 34 active and valid patents globally, expiring between 2025 and 2035. Additionally, 52 patent applications are pending, which, if approved, would expire between 2035 and 2044. The KIO-101 and KIO-104 portfolios cover composition-of-matter, formulations, and therapeutic uses. The KIO-301 portfolio covers composition-of-matter, methods of use, and formulations.
• Licensing Programs: Kiora Pharmaceuticals, Inc. is party to six license agreements, including:
  • An out-license agreement with Théa Open Innovation for global development and commercialization rights to KIO-301 (excluding certain Asian countries).
  • In-license agreements with Photoswitch Therapeutics, Inc. and the University of California for patent applications and exclusive rights to photoswitch molecules related to KIO-301.
  • An out-license agreement with 4SC for the compound used in KIO-101 and KIO-104 for rheumatoid arthritis and inflammatory bowel disease.
  • A patent and know-how assignment agreement with 4SC Discovery GmbH transferring rights to the compound used in KIO-101 and KIO-104 to Kiora Pharmaceuticals, Inc.
• IP Litigation: The company faces inherent risks of intellectual property litigation, including infringement claims by third parties or challenges to its own patent rights.

Technology Partnerships:

• Strategic Alliances: Théa Open Innovation (KIO-301 co-development and commercialization), Choroideremia Research Foundation (KIO-301 development support for Choroideremia).
• Research Collaborations: University of California (exclusive rights to photoswitch molecules).

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's future performance is significantly dependent on the continued service of its key scientific, technical, and senior management personnel, and its ability to attract and retain highly skilled employees. Employment agreements are in place for the CEO, CFO, and CDO.

Board Composition: The Board of Directors is responsible for assessing and managing information security matters, with the Audit Committee overseeing cybersecurity risk management processes. Specific details on board independence, expertise areas, or committee structure were not provided in the filing.

Human Capital Strategy

Workforce Composition:

• Total Employees: 12 full-time employees as of December 31, 2024.
• Skill Mix: Employees are highly skilled, with many holding advanced degrees and possessing experience in drug development.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Kiora Pharmaceuticals, Inc. faces intense competition for qualified scientific, clinical, manufacturing, and sales and marketing personnel.
• Employee Value Proposition: The company provides competitive salaries and bonuses, opportunities for equity ownership, development programs for continuous learning and growth, and a robust employment package that promotes overall employee well-being. This package includes potential annual discretionary bonuses, equity awards, healthcare and insurance benefits, paid time off, family leave, and flexible work schedules.

Diversity & Development:

• Development Programs: The company offers development programs that enable continued learning and growth for its employees.
• Culture & Engagement: Kiora Pharmaceuticals, Inc. aims to promote well-being across all aspects of its employees' lives and fosters a security culture that communicates risks, designs secure IT systems, and operates according to approved processes.

Environmental & Social Impact

Environmental Commitments: Kiora Pharmaceuticals, Inc. and its third-party manufacturers are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. The company contracts with third parties for waste disposal.

Supply Chain Sustainability: No specific information on supply chain sustainability initiatives or supplier engagement programs was disclosed in the filing.

Social Impact Initiatives: No specific social impact initiatives or community investment programs were disclosed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• United States: Pharmaceutical products are subject to extensive regulation by the FDA under the Food Drug and Cosmetic Act (FDCA), including requirements for preclinical testing (GLP), clinical trials (IND, IRB, GCP), manufacturing (CGMP), and marketing approval (NDA). KIO-301 has received Orphan Drug Designation under the Orphan Drug Act, which provides seven years of market exclusivity if it is the first FDA-approved product for the designated rare disease.
• International Compliance: Kiora Pharmaceuticals, Inc. must obtain separate marketing approvals and comply with numerous and varying regulatory requirements in foreign jurisdictions where it intends to market its products. The European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for KIO-301.

Trade & Export Controls:

• Export Restrictions: Various laws, regulations, and executive orders restrict the use and dissemination outside of the U.S., or sharing with certain non-U.S. nationals, of classified information, products, and technical data.
• Sanctions Compliance: The Foreign Corrupt Practices Act (FCPA) prohibits payments to foreign officials for influencing business decisions and requires accurate accounting records for international operations. Compliance with such laws is expensive and challenging, particularly in the pharmaceutical industry where government-operated hospitals and doctors may be considered foreign officials.

Legal Proceedings: Kiora Pharmaceuticals, Inc. is not currently a party to any material legal proceedings.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 36.26% for the year ended December 31, 2024, compared to -0.73% for 2023. The increase in 2024 was due to foreign and domestic pre-tax income, primarily from the upfront payment from Théa Open Innovation.
• Federal Net Operating Loss (NOL) Carryforwards: Approximately $31.7 million as of December 31, 2024, which carry forward indefinitely but are limited to 80% of taxable income.
• State Net Operating Loss Carryforwards: None as of December 31, 2024.
• Foreign Net Operating Loss Carryforwards: $12.8 million as of December 31, 2024, which carry forward indefinitely.
• Research and Development (R&D) Credit Carryforwards: No federal or state R&D credit carryforwards as of December 31, 2024.
• Geographic Tax Planning: Kiora Pharmaceuticals, Inc. operates through subsidiaries in the United States, Austria, and Australia. Its transfer pricing policies are formulated with third-party experts, but tax authorities may challenge these, potentially increasing overall tax liability.
• Tax Reform Impact: The Tax Cuts and Jobs Act (TCJA) limits NOL deductions to 80% of taxable income and eliminates carrybacks for post-2017 NOLs, but allows indefinite carryforwards.
• Section 382 Limitations: A formal Section 382 analysis in 2024 determined multiple ownership changes, resulting in annual limitations on NOL utilization (ranging from $170,643 to $494,650) and a Net Unrealized Built-In Loss (NUBIL) of $17,519,701. This led to a reduction of Federal NOL carryforwards by $9,126,676 for 2018-2022 tax years and a $3,146,111 unfavorable book-to-tax adjustment in 2023. The remaining NUBIL will be recognized in 2024 and 2025. Due to these limitations, all federal and state NOLs without an unlimited carryforward period and R&D credits are expected to expire unused.
• Tax Liability Adjustment: An increase of $2.3 million in tax liability was recognized in Q4 2024 due to new information from the Section 382 study and transfer pricing analysis.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Kiora Pharmaceuticals, Inc. obtains insurance for each clinical trial it performs and plans to increase coverage as clinical trials expand and commercialization commences. The company also maintains insurance coverage specifically for cybersecurity risks.
• Risk Transfer Mechanisms: Not explicitly detailed beyond the mentioned insurance coverages.